Forecast

The analysts' average price target is +80,11€ (+49,29%). The median is +77,23€ (+43,92%).

Buy	19
Hold	14
Sell	0

News Go to news feed

Strong quarterly results drive Ionis Pharmaceuticals stock higher premarket

Ionis Pharmaceuticals reported a loss per share of $0.69 and revenue of $268 million in the second quarter, with both metrics comfortably beating consensus expectations. The results point to faster‑than‑expected sales for Tryngolza (Olezarsen), despite a substantial price cut ahead of broader approval. After the stock plunged following the failure of the Phase‑3 CARDIO‑TTRansform study, the premarket recovery now reflects the solid commercial numbers and positive analyst commentary, with an average 12‑month price target of about $92.95. » More on de.investing.com
Ionis treats first patient in phase‑1/2 study of Dravet pill ION337

Ionis has treated the first participant in the open-label phase‑1/2 ASCEND study of ION337 for the treatment of Dravet syndrome. ION337 is intended to increase production of the NaV1.1 protein and uses the N‑methylacetamide (NMA) modification; the FDA has granted the drug Fast Track designation. The study includes a one-month single ascending dose phase followed by 24 months of multiple ascending dosing and a seven-month safety follow-up in children aged 2–12 years. Ionis most recently reported revenue of $1.06 billion (+48% year/year) but remains unprofitable with a loss of $2.02 per share; market capitalization is $9.63 billion and analysts' price targets range between $68 and $125. » More on de.investing.com
Study failure for eplontersen weighs on Ionis Pharmaceuticals stock

The phase‑3 CARDIO‑TTRansform study with eplontersen missed the primary endpoint of the composite of cardiovascular mortality and recurrent events through week 140, after which Ionis Pharmaceuticals shares fell about 20.7% in premarket trading. CARDIO‑TTRansform, with 1,432 patients, was the largest study to date in ATTR‑CM and was viewed as a key growth driver for Ionis through 2026. A pre‑specified subgroup analysis showed a nominally significant hazard ratio for eplontersen as monotherapy, but this was not enough to offset the failure of the overall study. The result strengthens competitors such as Alnylam in the ATTR‑CM market and forces investors to reassess the near‑term commercial prospects for eplontersen. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2000, Ionis Pharmaceut has already paid 0,67€ in dividends. The last payout was in May 2000.

Financials

In the last quarter, Ionis Pharmaceut had revenue of 234.78m€ and net profit of −100.45m€

(EUR)	Jun 2026	YoY
Revenue	+234.78m	38,78%
Gross profit	+232.38m	38,85%
Net profit	−100.45m	195,83%
EBITDA	−92.29m	172,41%

Fundamentals

Metric	Value
Market capitalization	+8.94b€
Number of shares	166.18m
52-week high/low	+74,43€ - +36,15€
Dividends	No
Beta	0,4
P/E ratio	−18,11
PEG ratio	+0,22
P/B ratio	+23,57
P/S ratio	+11,92

Company profile

Ionis Pharmaceuticals, Inc. erforscht und entwickelt in den Vereinigten Staaten RNA-gezielte Therapeutika. Das Unternehmen bietet SPINRAZA für spinale Muskelatrophie (SMA) bei pädiatrischen und erwachsenen Patienten, TEGSEDI, eine Injektion zur Behandlung der Polyneuropathie der hereditären Transthyretin-vermittelten Amyloidose bei Erwachsenen, und WAYLIVRA, eine Behandlung für das familiäre Chylomikronämie-Syndrom und die familiäre partielle Lipodystrophie. Darüber hinaus entwickelt das Unternehmen Medikamente für verschiedene Indikationen, die sich in Phase-3-Studien befinden, darunter Eplontersen als monatliche subkutane Injektion zur Selbstverabreichung zur Behandlung aller Arten von TTR-Amyloidose; Olezarsen für Patienten mit schwerer Hypertriglyceridämie (SHTG); Donidalorsen für Patienten mit hereditärem Angioödem; ION363 für Patienten mit amyotropher Lateralsklerose; Pelacarsen für Patienten mit etablierten Herz-Kreislauf-Erkrankungen und erhöhtem Lipoprotein(a); und Tofersen zur Hemmung der Produktion von Superoxid-Dismutase 1. Darüber hinaus entwickelt das Unternehmen Medikamente für Stoffwechselkrankheiten, Infektionskrankheiten, Nierenkrankheiten, Augenkrankheiten und Krebs. Es unterhält eine strategische Zusammenarbeit mit Biogen Inc. sowie Kooperations- und Lizenzvereinbarungen mit AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc. und Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. wurde 1989 gegründet und hat seinen Sitz in Carlsbad, Kalifornien.

Name	Ionis Pharmaceut
CEO	Brett Monia
Headquarters	Carlsbad, ca USA
Website	ionispharma.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	05/17/1991
Employees	1.480